DURECT (DRRX) Competitors $0.67 +0.00 (+0.51%) As of 10:04 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. IOBT, SRZN, MGNX, CLYM, CLLS, TCRX, OKYO, UNCY, PLRX, and JSPRShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include IO Biotech (IOBT), Surrozen (SRZN), MacroGenics (MGNX), Climb Bio (CLYM), Cellectis (CLLS), TScan Therapeutics (TCRX), OKYO Pharma (OKYO), Unicycive Therapeutics (UNCY), Pliant Therapeutics (PLRX), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Its Competitors IO Biotech Surrozen MacroGenics Climb Bio Cellectis TScan Therapeutics OKYO Pharma Unicycive Therapeutics Pliant Therapeutics Jasper Therapeutics IO Biotech (NASDAQ:IOBT) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation. Does the media favor IOBT or DRRX? In the previous week, IO Biotech had 1 more articles in the media than DURECT. MarketBeat recorded 1 mentions for IO Biotech and 0 mentions for DURECT. DURECT's average media sentiment score of 1.89 beat IO Biotech's score of 0.93 indicating that DURECT is being referred to more favorably in the news media. Company Overall Sentiment IO Biotech Positive DURECT Very Positive Do insiders and institutionals believe in IOBT or DRRX? 54.8% of IO Biotech shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 4.8% of IO Biotech shares are held by insiders. Comparatively, 3.2% of DURECT shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, IOBT or DRRX? DURECT has higher revenue and earnings than IO Biotech. DURECT is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIO BiotechN/AN/A-$95.49M-$1.37-1.08DURECT$2.03M10.24-$8.32M-$0.15-4.47 Which has more risk and volatility, IOBT or DRRX? IO Biotech has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Do analysts rate IOBT or DRRX? IO Biotech presently has a consensus target price of $9.33, indicating a potential upside of 528.51%. Given IO Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe IO Biotech is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IO Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is IOBT or DRRX more profitable? IO Biotech has a net margin of 0.00% compared to DURECT's net margin of -91.54%. IO Biotech's return on equity of -162.55% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets IO BiotechN/A -162.55% -125.08% DURECT -91.54%-267.36%-64.00% SummaryIO Biotech beats DURECT on 10 of the 16 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.80M$2.43B$5.50B$9.00BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-4.478.8826.5720.02Price / Sales10.24672.33415.46120.95Price / CashN/A151.5836.1356.90Price / Book2.314.618.065.50Net Income-$8.32M$31.16M$3.15B$248.50M7 Day Performance7.82%0.51%1.72%2.61%1 Month Performance17.13%7.63%3.92%5.42%1 Year Performance-47.66%1.44%35.02%20.76% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT1.1382 of 5 stars$0.67+0.5%N/A-51.0%$20.80M$2.03M-4.4780Positive NewsIOBTIO Biotech3.1081 of 5 stars$1.30flat$9.33+617.9%+26.3%$85.64MN/A-0.9530Gap UpSRZNSurrozen2.9822 of 5 stars$9.02-9.7%$38.50+326.8%-14.5%$85.54M$10.65M-0.3680MGNXMacroGenics4.1406 of 5 stars$1.32+0.8%$5.71+332.9%-66.3%$82.65M$149.96M-1.48430CLYMClimb Bio3.3046 of 5 stars$1.20-0.8%$9.00+650.0%N/A$81.77MN/A-0.509News CoveragePositive NewsCLLSCellectis3.0493 of 5 stars$1.44-2.0%$4.00+177.8%-12.2%$81.71M$49.22M-1.67290News CoverageTCRXTScan Therapeutics2.9426 of 5 stars$1.45+0.7%$7.80+437.9%-74.3%$81.49M$2.82M-1.33100Positive NewsOKYOOKYO Pharma2.6581 of 5 stars$2.19-7.6%$7.00+219.6%+142.5%$80.19MN/A0.007Gap UpUNCYUnicycive Therapeutics3.1608 of 5 stars$7.11+12.1%$60.00+743.9%-3.3%$80.14M$680K-1.399High Trading VolumePLRXPliant Therapeutics4.2501 of 5 stars$1.25-2.3%$13.31+965.0%-88.7%$78.57M$1.58M-0.3590Gap UpJSPRJasper Therapeutics2.0938 of 5 stars$5.13-0.4%$62.22+1,112.9%-70.1%$77.36MN/A-0.9820 Related Companies and Tools Related Companies IOBT Competitors SRZN Competitors MGNX Competitors CLYM Competitors CLLS Competitors TCRX Competitors OKYO Competitors UNCY Competitors PLRX Competitors JSPR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
